An interventional study of Blood sampling in Sickle Cell Disease, sponsored by Hanane EL KENZ. Completed at 2 sites in Belgium. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Hanane EL KENZ · Not applicable, Interventional, and Screening
Sickle cell patients have a high prevalence of alloimmunization. This high rate of alloimmunization can be partially explained by the existence of an antigenic difference between the predominantly Caucasian donor population and the sickle cell patients of African origin. Genetic and environmental risk factors have also been described.
The main risk factors that have been shown in retrospective or cross-sectional studies are some HLA alleles, the age of the patient, the number of leukocyte-depleted erythrocyte concentrates (CED) transfused, the number of transfusion episodes, the age of the CEDs, the existence of an inflammatory event at the time of transfusion and the presence of anti-erythrocyte autoantibodies.There is also evidence of an impaired TH response but the underlying immunological mechanism is not fully understood.
The aim of this study is to study the prevalence and the risk factors for anti-erythrocyte alloimmunization and to try to understand the immunological mechanisms.
Sickle cell disease patients treated within the CHU Brugmann or Queen Fabiola Children's Hospital
Exclusion Criteria:
None
Allo-immunization detected (positive response for irregular antibodies 2 to 4 weeks after a blood transfusion)
Procedure: Blood sampling
Allo-immunization not detected
Procedure: Blood sampling
Extra blood sampling at the time of a blood transfusion in order to perform the laboratory analysis
Irregular antibodies
Presence/abscence of irregular antibodies
Time frame: 1 hour before blood transfusion
Irregular antibodies
Presence/abscence of irregular antibodies
Time frame: Between 2 to 4 weeks after blood transfusion
C-reactive protein (CRP)
CRP dosage
Time frame: 1 hour before blood transfusion
Cytokine
Cytokine dosage
Time frame: 1 hour before blood transfusion
Cytokine
Cytokine dosage
Time frame: Between 2 to 4 weeks after blood transfusion
Heme oxygenase
Heme oxygenase dosage
Time frame: 1 hour before blood transfusion
Heme oxygenase
Heme oxygenase dosage
Time frame: Between 2 to 4 weeks after blood transfusion
Lymphocyte typing
Lymphocyte typing
Time frame: 1 hour before blood transfusion
Lymphocyte typing
Lymphocyte typing
Time frame: Between 2 to 4 weeks after blood transfusion
Sex
Sex
Time frame: 1 hour before blood transfusion
Chronic or acute blood transfusion
Blood transfusions planned at regular intervals of time (chronic transfusions) or performed in reaction to a medical issue (acute transfusion).
Time frame: 1 hour before blood transfusion
Blood transfusion indication
Medical reason explaining the necessity of a blood transfusion
Time frame: 1 hour before blood transfusion
Blood donor ethnicity
Blood donor ethnicity
Time frame: 1 hour before blood transfusion
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hanane EL KENZ